| Events
Column |
|
|
5/21
6:30 pm - 9:30 pm. Licensing Executives Society CT Chapter. "Burning
Intellectual Property Issues of 2008: Patent Reform and
Why It Was Blocked in Court; Supreme Court Rulings of 2007
and Their Effects in 2008 and Beyond." President's
Room, Woolsey Hall, Yale University, 500 College St., New
Haven. more |
|
| 5/22
1:00 pm - 3:00 pm.
Biobanks: The Promise and Public Health Challenges of
Biorepositories for Genomics Research. Presented by The CT
Dept of Public Health Virtual Office of Genomics. Crowne
Plaza, 100 Berlin Road, Cromwell. more |
|
|
6/18
12:00
noon - 1:00 pm.
Brown Bag Lunch. "Stem Cells: Everything You Wanted
to Know But Were Afraid to Ask." Presented by the
Yale Stem Cell Center. TAC Auditorium, N107, Yale
University, New Haven more
|
|
|
|
Connecticut
Stem Cell Activities Accelerate
From
the desk of Paul Pescatello, President and CEO of CURE
 Stem
cells are in the news again, and Connecticut continues to be
on the cutting edge of progress in this important research. The state's Stem Cell Research Advisory Committee has directed the allocation of $9.84 million in stem cell research funds to scientists based in Storrs, Farmington, and New Haven.
The awards come at a time when stem cell research is opening new vistas in bioscience research.
For
the full story |
|
Panel
Discusses 'The Next Big Idea' in Bioscience
CURE/Yale
BioHaven Entrepreneuship Series Continues
 A
special panel discussion, "The Next Big Idea -
Emerging
Opportunities in the Life Sciences," took place April 16
at Yale's Anlyan Center as part of the CURE/Yale BioHaven
Entrepreneurship Series. Introduced by Jon Soderstrom,
managing director of the Yale Office of Cooperative
Research, the panel included Roger Longman, managing partner
at Windhover Information; William Burkoth, senior manager
venture capital at Pfizer Venture Investments; Dr. Richard
Flavell, chairman of the Immunobiology Department at Yale
and founding scientist of VaxInnate; Haifan Lin, director of
the Yale Stem Cell Center; and venture capitalist David
Scheer, president of Scheer & Company, Inc.
For
the full story |
|
Life
Sciences Drew Bulk of 2007 CT Venture Capital
Of
the venture capital invested in Connecticut companies in
2007, more than three quarters was attracted by life
sciences companies, according to a CURE analysis of
MoneyTree™ reports from PricewaterhouseCoopers and the
National Venture Capital Association, based on data provided
by Thomson Reuters. "Life Sciences" includes
Biotechnology and Medical Devices & Equipment.
For
the full story |
|
Vidus
Ocular Presents New Glaucoma Device
CURE/Yale
BioHaven Entrepreneuship Series Continues
 Vidus Ocular presented its new device for treatment of glaucoma at a seminar April 23 at Yale’s Anlyan Center, as part of the CURE/Yale BioHaven Entrepreneurship Series. John Puziss, director of technology licensing at the Yale Office of Cooperative Research, introduced Dr. Ben R. Bronstein, co-founder, president, and chief operating officer of Vidus Ocular, and Dr. Bruce Shields, who is co-founder and chief scientific and medical
officer of Vidus Ocular and the Marvin L. Sears professor and chairman emeritus of the Department of Ophthalmology at Yale University School of Medicine.
For
the full story |
|
CURE
Member News Digest
 Alexion
reports
dramatic increase in Q1 revenue
Bayer
HealthCare unveils VistTrak™ plans
Boehringer
Ingelheim finds MICARDIS® effective
Bristol-Myers
Squibb selects cholesterol candidate
CMD
Bioscience signs licensing agreement
Connecticut
Innovations assists stem cell funding
CuraGen
sells belinostat interest
GlaxoSmithKline
acquires Sirtris
HistoRx
signs deal with Lilly
Invitrogen
to distribute mitochondrial products
Johnson
& Johnson comments on Q1
MannKind
welcomes Matthew Pfeffer as CFO
NanoViricides
commences Boston trials
Neurogen grosses
$30.6 million in private placement
Optherion featured
in Forbes article
Purdue
Pharma introduces new OxyContin® dosages
Pfizer
reports benefits in 80 mg Lipitor®
PhRMA
heralds Global Health Progress launch
Quinnipiac
professor named Fulbright scholar
Rib-X
Pharmaceuticals renews crystal structure pact
Nine
UConn
faculty get stem cell funding
Yale
clones ovarian cancer stem cells
For
the full story |
|
